Phaseline

Targets › B3H3

B3H3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2034.

Open in Phaseline: the race on B3H3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
St. Jude Children's Research HospitalSJCARB7H3_41BBL
B7-H3-directed CAR T cell therapy with 4-1BB costimulatory domain
B3H3Phase 2Pediatric OsteosarcomaDec 2034

Conditions

Pediatric Osteosarcoma (1)

Modalities

small molecule (1)

Companies

St. Jude Children's Research Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.